41 results
Page 2 of 3
8-K
EX-99.1
6vyyschrk1x
10 Aug 23
Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:08pm
8-K
EX-10.1
28w4p1165plhxz 9l08g
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
sbgez lj3
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
5kz0ek2v4ojo6c6
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
32zp0rur c5wb5b2m
8 May 23
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:13pm
10-K/A
rbnjg3g qa0fupbjptc
28 Apr 23
Annual report (amended)
4:15pm
8-K
EX-99.1
5wstun5swrr75xpz
18 Apr 23
ZW191 demonstrates strong responses in FRĪ±-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles
4:18pm
8-K
EX-99.1
uzjrgiy eltpfcw
10 Apr 23
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
4:46pm
DEF 14A
76wl14e sglf
25 Nov 22
Definitive proxy
6:16am
424B5
ajgs50fddtlj2zael
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
juos1wy4sakqx0is2in
8 Nov 22
Quarterly report
4:09pm
424B5
qxtrfyh8e 4jsfcymr
21 Oct 22
Prospectus supplement for primary offering
4:16pm
424B5
q80t121fz xz
13 Oct 22
Prospectus supplement for primary offering
4:56pm
8-K12B
44jrp9law
13 Oct 22
Notification of registration of securities
7:24am
424B3
m5hoctpbrjx9s35b gpi
2 Sep 22
Prospectus supplement
4:06pm
S-4/A
jp23c1g5wfl8g7psn
19 Aug 22
Registration of securities issued in business combination transactions (amended)
4:47pm
425
1lc091l
15 Jul 22
Business combination disclosure
5:26pm
425
5kticg8011gbz76esfgy
15 Jul 22
Business combination disclosure
5:23pm
425
s9wd nx33
15 Jul 22
Business combination disclosure
5:12pm